At the end of 2023, more than one-third of new prescriptions to treat Type 2 diabetes were GLP-1s, such as Mounjaro and Ozempic, among others, according to a study published April 15 in Annals of Internal Medicine. Researchers at Mass…
GLP-1s
Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant “experienced potential drug-induced liver injury,” the company said April 14. In dose-optimization studies, once-daily danuglipron met pharmacokinetic endpoints and showed potential for promising…
CMS said April 4 it will not move forward with a Biden-era proposal to allow Medicare coverage of GLP-1 drugs when prescribed solely for weight loss. Three notes: 1. While the agency is not currently moving forward with a proposal…
Mounjaro (tirzepatide) led to greater weight loss and better glucose control than high doses of Trulicity (dulaglutide), according to a study published April 4 in Annals of Internal Medicine. A common challenge for physicians prescribing GLP-1s is whether to increase…
A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 among U.S. adults without diabetes. The research, published April 1 in the Annals of Internal Medicine, showed the number…
Advertisement
Four blockbuster GLP-1 medications are expected to be among the 10 best-selling drugs in 2026, accounting for $66.8 billion in global sales, according to market research company Statista Statista predicts Ozempic will yield $22.3 billion in 2026, followed by Mounjaro…
With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic and Wegovy set for later this spring, the agency is meeting resistance from telehealth companies and compounding pharmacies that are…
In 2023, the United States marked a major milestone in the battle against a longstanding public health crisis: adult obesity rates dropped for the first time in a decade. Researchers pointed to GLP-1s as a potential contributing factor, alongside pandemic-related…
A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and conducted by University of Chicago researchers, found that to…
Glucagon-like peptide-1 receptor agonists such as Ozempic, originally developed for diabetes management and later approved for weight loss, are being studied for their potential to address age-related diseases, The Wall Street Journal reported March 10.